Ryman Healthcare Ltd
RYM: XNZE (NZL)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
NZD 9.70 | Wqynqxs | Kvmwvvjfv |
Ryman Healthcare’s Short-Term Earnings Not Immune to COVID-19, but Our NZD 13.00 FVE Is Retained
We expect narrow-moat Ryman Healthcare to face short-term margin compression and lower unit sale volumes amid the unfolding COVID-19 pandemic, however, we anticipate conditions to improve from fiscal 2022. This weakness is likely short term and immaterial to our long-term forecasts. In turn, we reiterate our fair value estimate of NZD 13.00 per share.